Hot topics close

Delta COVID variant becoming globally dominant, WHO official says

Delta COVID variant becoming globally dominant WHO official says
The Delta variant of COVID-19, first identified in India, is becoming the globally dominant variant of the disease, the World Health Organization's chief scientist said on Friday.

A logo is pictured outside a building of the World Health Organization (WHO) during an executive board meeting on update on the coronavirus disease (COVID-19) outbreak, in Geneva, Switzerland, April 6, 2021. REUTERS/Denis Balibouse/File Photo

  • Delta variant, first identified in India, fast becoming dominant
  • WHO scientist had expected more from CureVac shot candidate
  • Africa trajectory 'concerning' amid dearth of vaccines

GENEVA, June 18 (Reuters) - The Delta variant of COVID-19, first identified in India, is becoming the globally dominant variant of the disease, the World Health Organization's chief scientist said on Friday.

Soumya Swaminathan also voiced disappointment in the failure of CureVac's (5CV.DE) vaccine candidate in a trial to meet the WHO's efficacy standard, in particular as highly transmissible variants boost the need for new, effective shots. read more

Britain has reported a steep rise in infections with the Delta variant, while Germany's top public health official predicted it would rapidly become the dominant variant there despite rising vaccination rates. read more

The Kremlin blamed a surge in COVID-19 cases on reluctance to have vaccinations and "nihilism" after record new infections in Moscow, mostly with the new Delta variant, fanned fears of a third wave. read more

"The Delta variant is well on its way to becoming the dominant variant globally because of its increased transmissibility," Swaminathan told a news conference.

Coronavirus variants were cited by CureVac when the German company this week reported its vaccine proved only 47% effective at preventing disease, shy of the WHO's 50% benchmark.

The company said it documented at least 13 variants circulating within its study population.

Given that similar mRNA vaccines from Pfizer (PFE.N) and BioNTech (22UAy.DE) and Moderna (MRNA.O) posted efficacy rates topping 90%, Swaminathan said the world had been expecting more from CureVac's candidate.

"Just because it's another mRNA vaccine, we cannot presume all mRNA vaccines are the same, because each one has a slightly different technology," Swaminathan said, adding the surprise failure underscored the value of robust clinical trials to test new products.

WHO officials said Africa remains an area of concern, even though it accounts for only around 5% of new global infections and 2% of deaths. read more

New cases in Namibia, Sierra Leone, Liberia and Rwanda have doubled in the last week, WHO emergencies programme head Mike Ryan said, while vaccine access remains miniscule.

"It's a trajectory that is very, very concerning," Ryan said. "The brutal reality is that in an era of multiple variants, with increased transmissibility, we have left vast swathes of the population, the vulnerable population of Africa, unprotected by vaccines."

Reporting by John Miller and Mike Shields, writing by Giles Elgood, Editing by Catherine Evans

Our Standards: The Thomson Reuters Trust Principles.

Similar shots
News Archive
  • Katie Ledecky
    Katie Ledecky
    When is Katie Ledecky's next race? What to know as she chases ...
    31 Jul 2024
    23
  • Yankees vs Guardians
    Yankees vs Guardians
    Instant analysis: Yankees bullpen falls apart in dramatic Game 3 ...
    18 Oct 2024
    3
  • Trump vs biden polls
    Trump vs biden polls
    Some Americans say they want to leave if Trump wins again. Here’s what life abroad is like for expats
    2 Nov 2020
    1
  • Dave Hebner
    Dave Hebner
    Dave Hebner Passes Away – IMPACT Wrestling
    19 Jun 2022
    2
  • Wayne Swinny
    Wayne Swinny
    Wayne Swinny Dead: Saliva Guitarist, 59, Suffered Hemorrhage on ...
    23 Mar 2023
    3
This week's most popular shots